Summary
46 / 100 · Bulios Score
What speaks for it
- It passes 8 of the 9 points of the Piotroski financial health test.
What to watch
- It pays out more in dividends than it earns: 402% of profit.
- The share price is above the Bulios Fair Price.
- Revenue growth is slowing: 2.7% a year over the last 3 years against 14% over 5 years.
- Out of every 100 USD of revenue, only 0.2 USD is left as net profit.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 224.0 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 14% a year over 5 years. Over the last 3 years it grew by 2.7% a year. For the next fiscal year analysts expect revenue to grow by 4.4%.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 81 USD
- Sales and administration 12 USD
- Taxes and other 7.3 USD
- Net profit 0.2 USD
Net profit, industry median (Industrial Materials) 11 USD
Out of every 100 USD of revenue, 0.2 USD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenOver the last 12 months it spent more cash than it brought in. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Small, at risk- Yield
- 1.80%
- Paid out of profit
- 402%
- Raised in a row
- 1 year
You receive $0.47 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.